Drug Trial Radar · NCT02892344
Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma
Last checked: Nov 19, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
802
Actual
Start
Jan 16, 2017
Primary completion
Nov 5, 2018
Study completion Nov 30, 2018
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 8, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the trial was to evaluate efficacy and safety of QMF149 150/80 microgram o.d. delivered via Concept1 compared to MF 200 microgram o.d., delivered via Twisthaler® in terms of lung function and symptom control in poorly (ie inadequately) controlled asthma patients. This study was to assess contribution of LABA as an add-on therapy to low dose ICS monotherapy.
Conditions
- Mild Asthma
Interventions
QMF149 150/80 μgDrug
QMF149 150/80 μg o.d via Concept1
MF 200 μgDrug
MF 200 μg o.d. via Twisthaler®
Primary outcomes
What the sponsor says the trial is designed to measure.
- Trough FEV1Time frame: week 12
Locations
123 sites in 22 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Pleven, Bulgaria
Novartis Investigative Site
Bulgaria, Bulgaria, Bulgaria
Novartis Investigative Site
Stara Zagora, Bulgaria, Bulgaria
Novartis Investigative Site
Santiago, Chile
Novartis Investigative Site
Santiago, Chile
Novartis Investigative Site
Viña del Mar, Chile
Novartis Investigative Site
Santiago, Santiago Metropolitan, Chile
Novartis Investigative Site
Bogotá, Colombia
Novartis Investigative Site
Medellín, Antioquia, Colombia
Novartis Investigative Site
Bucaramanga, Colombia, Colombia
Novartis Investigative Site
Medellín, Colombia, Colombia
Novartis Investigative Site
Bogota, Cundinamarca, Colombia
Novartis Investigative Site
Kohtla-Järve, Estonia
Novartis Investigative Site
Tallinn, Estonia
Novartis Investigative Site
Tartu, Estonia
Novartis Investigative Site
Tartu, Estonia, Estonia
Novartis Investigative Site
Bad Wörishofen, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Darmstadt, Germany
Novartis Investigative Site
Frankfurt, Germany
Novartis Investigative Site
Gauting, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Hanover, Germany
Novartis Investigative Site
Landsberg, Germany
Novartis Investigative Site
Leipzig, Germany
Novartis Investigative Site
Lübeck, Germany
Novartis Investigative Site
Mainz, Germany
Novartis Investigative Site
Bochum, Germany, Germany
Novartis Investigative Site
Marburg, Germany, Germany
Novartis Investigative Site
Cegléd, Hungary
Novartis Investigative Site
Gödöllő, Hungary
Novartis Investigative Site
Győr, HUN, Hungary
Novartis Investigative Site
Százhalombatta, HUN, Hungary
Novartis Investigative Site
Szarvas, Hungary, Hungary
Novartis Investigative Site
Szeged, Hungary, Hungary
Novartis Investigative Site
Törökbálint, Pest County, Hungary
Novartis Investigative Site
Ahmedabad, Gujarat, India
Novartis Investigative Site
Vadodara, Gujarat, India
Novartis Investigative Site
Bangalore, Karnataka, India
Novartis Investigative Site
Hubli, Karnataka, India
Showing 40 of 123 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.